These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37831324)

  • 1. Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
    Kirsch-Stefan N; Guillen E; Ekman N; Barry S; Knippel V; Killalea S; Weise M; Wolff-Holz E
    BioDrugs; 2023 Nov; 37(6):855-871. PubMed ID: 37831324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the EU Biosimilar Framework: Past and Future.
    Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
    BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
    Barbier L; Declerck P; Simoens S; Neven P; Vulto AG; Huys I
    Br J Cancer; 2019 Jul; 121(3):199-210. PubMed ID: 31257362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.
    Vezér B; Buzás Z; Sebeszta M; Zrubka Z
    Curr Med Res Opin; 2016 May; 32(5):829-34. PubMed ID: 26808864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials for authorized biosimilars in the European Union: a systematic review.
    Mielke J; Jilma B; Koenig F; Jones B
    Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies.
    Guillen E; Ekman N; Barry S; Weise M; Wolff-Holz E
    Clin Pharmacol Ther; 2023 Jan; 113(1):108-123. PubMed ID: 36546547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.
    Alsamil AM; Giezen TJ; Egberts TC; Leufkens HG; Vulto AG; van der Plas MR; Gardarsdottir H
    Eur J Pharm Sci; 2020 Nov; 154():105501. PubMed ID: 32739253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
    Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
    Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.
    Coory M; Thornton K
    Breast Cancer Res Treat; 2019 Jul; 176(1):17-25. PubMed ID: 30980209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
    Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
    JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
    J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
    Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
    Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the animal studies conducted for biosimilar approvals - Regulatory requirement vs actual scenario.
    Pipalava P; Patel R; Mehta M; Dahiya M; Singh I; Jose V
    Regul Toxicol Pharmacol; 2019 Oct; 107():104415. PubMed ID: 31254556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of animal studies to evaluate the similarity of biosimilars to reference products.
    van Meer PJ; Ebbers HC; Kooijman M; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    Drug Discov Today; 2015 Apr; 20(4):483-90. PubMed ID: 25463036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.